Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment.
Chemoresistance
Mucin
Mucinous ovarian carcinoma
Targeted therapy
Tumorigenesis
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
19
07
2023
revised:
11
08
2023
accepted:
16
08
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Mucinous ovarian carcinoma (MOC) is a rare histological type of epithelial ovarian cancer. It has poor response to conventional platinum-based chemotherapy regimens and PARPi-based maintenance treatment, resulting in short survival and poor prognosis in advanced-disease patients. MOC is characterized by mucus that is mainly composed of mucin in the cystic cavity. Our review discusses in detail the role of mucins in MOC. Mucins are correlated with MOC development. Furthermore, they are valuable in the differential diagnosis of primary and secondary ovarian mucinous tumors. Some types of mucins have been studied in the context of chemoresistance and targeted therapy for ovarian cancer. This review may provide a new direction for the diagnosis and treatment of advanced MOC.
Identifiants
pubmed: 37664708
doi: 10.1016/j.heliyon.2023.e19221
pii: S2405-8440(23)06429-0
pmc: PMC10468386
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e19221Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cell. 2020 Oct 29;183(3):717-729.e16
pubmed: 33031746
Pathol Res Pract. 2004;200(5):371-7
pubmed: 15239345
Expert Rev Vaccines. 2008 Sep;7(7):963-75
pubmed: 18767946
Int J Gynecol Cancer. 2023 Jan 3;33(1):102-108
pubmed: 36603894
BMC Cancer. 2014 Apr 01;14:234
pubmed: 24690311
Virchows Arch. 2019 Mar;474(3):289-296
pubmed: 30631934
Cancer Metastasis Rev. 2019 Jun;38(1-2):237-257
pubmed: 30680581
Am J Surg Pathol. 2003 Jul;27(7):985-93
pubmed: 12826891
Curr Opin Struct Biol. 2023 Apr;79:102524
pubmed: 36753925
Eur J Pharmacol. 2018 Sep 5;834:188-196
pubmed: 30031797
Mod Pathol. 2019 Dec;32(12):1834-1846
pubmed: 31239549
Immunotherapy. 2010 May;2(3):305-27
pubmed: 20635898
PLoS One. 2015 Jun 15;10(6):e0130197
pubmed: 26075384
Hum Pathol. 2000 Jun;31(6):672-7
pubmed: 10872659
Acta Histochem Cytochem. 2008 Apr 26;41(2):15-21
pubmed: 18493590
Lancet Oncol. 2011 Oct;12(11):1071-80
pubmed: 21616717
Semin Cancer Biol. 2021 Dec;77:42-55
pubmed: 33812984
J Clin Oncol. 2004 Mar 15;22(6):1040-4
pubmed: 15020606
Gynecol Oncol. 2021 Dec;163(3):473-480
pubmed: 34627611
Pathol Res Pract. 2021 Aug;224:153533
pubmed: 34171599
Jpn J Clin Oncol. 2010 Mar;40(3):208-13
pubmed: 19926591
J Biol Chem. 2004 Mar 5;279(10):9190-8
pubmed: 14676194
Biochim Biophys Acta. 2014 Aug;1846(1):142-51
pubmed: 24785432
Cancer Invest. 2012 Oct;30(8):577-82
pubmed: 22812695
Oncogene. 2013 Mar 28;32(13):1714-23
pubmed: 22580602
Clin Chem Lab Med. 2022 Nov 17;61(3):464-472
pubmed: 36380677
Int J Gynecol Cancer. 2022 May 3;32(5):662-668
pubmed: 35185017
Breast Cancer Res Treat. 2009 Nov;118(1):113-24
pubmed: 19415485
Gynecol Oncol. 2020 Mar;156(3):552-560
pubmed: 31902686
Gynecol Oncol. 2019 Aug;154(2):302-307
pubmed: 31155308
Br J Cancer. 2006 Mar 27;94(6):904-13
pubmed: 16508639
Int J Gynecol Pathol. 2014 Mar;33(2):166-75
pubmed: 24487472
Biol Cell. 2004 Mar;96(2):145-51
pubmed: 15050369
Surg Pathol Clin. 2019 Jun;12(2):565-585
pubmed: 31097115
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68
pubmed: 29718305
J Clin Oncol. 2013 Apr 20;31(12):1554-61
pubmed: 23478059
ESMO Open. 2022 Feb;7(1):100311
pubmed: 34920291
Acta Histochem Cytochem. 2021 Aug 25;54(4):115-122
pubmed: 34511650
J Immunol. 2013 Jun 1;190(11):5600-8
pubmed: 23630346
Diagnostics (Basel). 2020 Jan 19;10(1):
pubmed: 31963927
Cancer Res. 2009 Feb 1;69(3):765-74
pubmed: 19176398
J Gynecol Oncol. 2022 Mar;33(2):e18
pubmed: 34910399
Histopathology. 2010 Oct;57(4):597-606
pubmed: 20955385
BMC Cancer. 2020 Jul 20;20(1):678
pubmed: 32689954
Eur J Cancer. 2016 Aug;63:55-63
pubmed: 27285281
Cancer Immunol Immunother. 2006 Nov;55(11):1337-47
pubmed: 16485130
Int J Mol Med. 2017 Aug;40(2):293-302
pubmed: 28586014
Gynecol Oncol. 2019 Jun;153(3):541-548
pubmed: 31005287
Sci Transl Med. 2019 Jun 19;11(497):
pubmed: 31217340
Case Rep Gastroenterol. 2011 Jan;5(1):5-16
pubmed: 22347149
N Engl J Med. 2019 Mar 28;380(13):1256-1266
pubmed: 30917260
Gynecol Oncol. 2009 Jun;113(3):331-4
pubmed: 19275957
Front Immunol. 2021 Apr 14;12:663379
pubmed: 33936101
Gynecol Oncol. 2013 Nov;131(2):451-9
pubmed: 23933187
Nat Commun. 2019 Sep 2;10(1):3935
pubmed: 31477716
J Gynecol Oncol. 2015 Apr;26(2):87-9
pubmed: 25872889
Int J Gynecol Pathol. 2002 Oct;21(4):391-400
pubmed: 12352188
Annu Rev Physiol. 1995;57:635-57
pubmed: 7778881
Int J Gynecol Cancer. 2018 Nov;28(9):1643-1649
pubmed: 30365456
Asian Pac J Cancer Prev. 2013;14(1):127-31
pubmed: 23534710
J Ovarian Res. 2011 Apr 26;4(1):7
pubmed: 21521521
J Cell Mol Med. 2021 Mar;25(6):3031-3040
pubmed: 33543559
J Immunother. 2009 Jan;32(1):54-65
pubmed: 19307994
Clin Cancer Res. 2010 Jul 15;16(14):3594-606
pubmed: 20628030
Gynecol Oncol. 2020 Mar;156(3):523-529
pubmed: 31916979
Am J Surg Pathol. 2011 Dec;35(12):1830-6
pubmed: 21881489
J Immunother Cancer. 2014 Jun 18;2:16
pubmed: 24995129
BMC Cancer. 2023 Jan 13;23(1):44
pubmed: 36639622
Gynecol Oncol. 2009 Dec;115(3):407-13
pubmed: 19747716
Ann Oncol. 2016 Nov;27(11):2124-2130
pubmed: 27793850
Oncogenesis. 2020 Jul 1;9(6):61
pubmed: 32612258
J Clin Oncol. 2004 Sep 1;22(17):3507-16
pubmed: 15337799